Document Detail


Aurora B is regulated by the mitogen-activated protein kinase/extracellular signal-regulated kinase (MAPK/ERK) signaling pathway and is a valuable potential target in melanoma cells.
MedLine Citation:
PMID:  22767597     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Metastatic melanoma is a deadly skin cancer and is resistant to almost all existing treatment. Vemurafenib, which targets the BRAFV600E mutation, is one of the drugs that improves patient outcome, but the patients next develop secondary resistance and a return to cancer. Thus, new therapeutic strategies are needed to treat melanomas and to increase the duration of v-Raf murine sarcoma viral oncogene homolog B1 (BRAF) inhibitor response. The ERK pathway controls cell proliferation, and Aurora B plays a pivotal role in cell division. Here, we confirm that Aurora B is highly expressed in metastatic melanoma cells and that Aurora B inhibition triggers both senescence-like phenotypes and cell death in melanoma cells. Furthermore, we show that the BRAF/ERK axis controls Aurora B expression at the transcriptional level, likely through the transcription factor FOXM1. Our results provide insight into the mechanism of Aurora B regulation and the first molecular basis of Aurora B regulation in melanoma cells. The inhibition of Aurora B expression that we observed in vemurafenib-sensitive melanoma cells was rescued in cells resistant to this drug. Consistently, these latter cells remain sensitive to the effect of the Aurora B inhibitor. Noteworthy, wild-type BRAF melanoma cells are also sensitive to Aurora B inhibition. Collectively, our findings, showing that Aurora B is a potential target in melanoma cells, particularly in those vemurafenib-resistant, may open new avenues to improve the treatment of metastatic melanoma.
Authors:
Caroline Bonet; Sandy Giuliano; Mickaël Ohanna; Karine Bille; Maryline Allegra; Jean-Philippe Lacour; Philippe Bahadoran; Stéphane Rocchi; Robert Ballotti; Corine Bertolotto
Related Documents :
21317457 - Sumoylation of vimentin354 is associated with pias3 inhibition of glioma cell migration.
3720057 - The invasive edge: invasion in colorectal cancer.
21376227 - The ribosome and torc2: collaborators for cell growth.
18621387 - Cellular clot formation in a sipunculan worm: entrapment of foreign particles, cell dea...
21189867 - Gene expression profiles in human peripheral blood mononuclear cells as biomarkers for ...
20804217 - Proteomic profile regulated by the anticancer peptide cigb-300 in non-small cell lung c...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't     Date:  2012-07-05
Journal Detail:
Title:  The Journal of biological chemistry     Volume:  287     ISSN:  1083-351X     ISO Abbreviation:  J. Biol. Chem.     Publication Date:  2012 Aug 
Date Detail:
Created Date:  2012-08-27     Completed Date:  2012-11-19     Revised Date:  2013-08-27    
Medline Journal Info:
Nlm Unique ID:  2985121R     Medline TA:  J Biol Chem     Country:  United States    
Other Details:
Languages:  eng     Pagination:  29887-98     Citation Subset:  IM    
Affiliation:
Inserm U1065, Centre Méditerranéen de Médecine Moléculaire, Equipe 1, Biologie et Pathologies des Mélanocytes de la Pigmentation Cutanée au Mélanome, Nice F-06204, France.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Amino Acid Substitution
Animals
Cell Aging / drug effects,  genetics
Cell Death / drug effects,  genetics
Cell Division / drug effects,  genetics
Cell Line, Tumor
Drug Resistance, Neoplasm / drug effects,  genetics
Forkhead Transcription Factors / genetics,  metabolism
Gene Expression Regulation, Enzymologic*
Gene Expression Regulation, Neoplastic*
Indoles / pharmacology
MAP Kinase Signaling System*
Melanoma / enzymology*,  genetics,  pathology,  therapy
Mice
Mutation, Missense
Neoplasm Metastasis
Protein-Serine-Threonine Kinases / antagonists & inhibitors,  biosynthesis*,  genetics
Proto-Oncogene Proteins B-raf / antagonists & inhibitors,  genetics,  metabolism
Skin Neoplasms / enzymology*,  genetics,  pathology,  therapy
Sulfonamides / pharmacology
Chemical
Reg. No./Substance:
0/FOXM1 protein, human; 0/Forkhead Transcription Factors; 0/Foxm1 protein, mouse; 0/Indoles; 0/PLX4032; 0/Sulfonamides; EC 2.7.11.1/BRAF protein, human; EC 2.7.11.1/Braf protein, mouse; EC 2.7.11.1/Protein-Serine-Threonine Kinases; EC 2.7.11.1/Proto-Oncogene Proteins B-raf; EC 2.7.11.1/aurora kinase

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Structural study reveals that Ser-354 determines substrate specificity on human histidine decarboxyl...
Next Document:  Visfatin/pre-B-cell colony-enhancing factor (PBEF), a proinflammatory and cell motility-changing fac...